目的 觀察二十五味鬼臼丸聯(lián)合頭孢曲松鈉治療慢性盆腔炎的臨床療效。方法 選取中國(guó)人民解放軍第四五七醫(yī)院2016年1月-2016年12月收治的慢性盆腔炎患者106例，隨機(jī)分為對(duì)照組和治療組，每組各53例。對(duì)照組患者靜脈滴注注射用頭孢曲松鈉，2 g加入生理鹽水250 mL，1次/d；治療組在對(duì)照組的基礎(chǔ)上口服二十五味鬼臼丸，5丸/次，2次/d。兩組患者均治療2周。評(píng)價(jià)兩組患者臨床療效，同時(shí)比較治療前后兩組患者臨床癥狀評(píng)分和炎癥因子指標(biāo)水平。結(jié)果 治療后，對(duì)照組臨床有效率為73.58%，顯著低于治療組的90.57%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組腹墜痛、白帶增多、白帶異味和月經(jīng)異常評(píng)分均顯著降低，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組上述臨床癥狀評(píng)分明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組超敏C反應(yīng)蛋白（hs-CRP）和白細(xì)胞介素-6（IL-6）水平均顯著降低，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組比對(duì)照組降低更明顯（P<0.05）。結(jié)論 二十五味鬼臼丸聯(lián)合頭孢曲松鈉治療慢性盆腔炎療效確切，不良反應(yīng)較輕，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To observe the curative effect of Ershiwuwei Guijiu Pills combined with ceftriaxone sodium in treatment of chronic pelvic inflammatory disease. Methods Patients (106 cases) with chronic pelvic inflammatory disease in 457 Military Hospital of China from January 2016 to December 2016 were randomly divided into control and treatment groups, and each group had 53 cases. Patients in the control group were iv administered with Ceftriaxone Sodium for injection, 2 g added into normal saline 250 mL, once daily. Patients in the treatment group were po administered with Ershiwuwei Guijiu Pills on the basis of the control group, 5 pills/time, twice daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the clinical symptom scores, inflammatory factors levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 73.58%, which was significantly lower than 90.57% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the abdominal pain, leukorrhagia, leucorrhoea peculiar smell and abnormal menstruation scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the clinical symptom scores in the treatment group after treatment were significantly lower than that in the control group, with significant difference between two groups (P<0.05). After treatment, the hs-CRP and IL-6 levels in two groups were significantly decreased, and there were differences in the same group (P<0.05). And the inflammatory factors levels in the treatment group after treatment were significantly lower than those in the control group (P<0.05). Conclusion Ershiwuwei Guijiu Pills combined with ceftriaxone sodium has obvious curative effect in treatment of chronic pelvic inflammatory disease with less adverse reactions, which has a certain clinical application value.